MANSOUREH BARADARAN | Medicine and Dentistry | Best Researcher Award

Posted on by sciencefather

Dr MANSOUREH BARADARAN | Medicine and Dentistry | Best Researcher Award

Dr.mansoureh baradaran, North Khorasan University of Medical Sciences, Iran 

Dr. Mansoureh Baradaran is a board-certified radiologist in Iran, with extensive experience in diagnostic imaging and research collaborations. She holds expertise in conducting systematic reviews and meta-analyses in the radiology field, focusing on neurological, oncological, and radiomics studies. Dr. Baradaran has been involved in collaborative projects with prestigious institutions like UCLA, UCSD, and UAB, working on cutting-edge research in artificial intelligence applications in healthcare. Her clinical skills include professional reporting on a variety of imaging modalities, including whole-body MRI and CT scans, mammography, and ultrasound. Throughout her career, she has authored numerous research papers and book chapters in the field of radiology. Dr. Baradaran is passionate about integrating modern technologies like AI into medical imaging and improving diagnostic accuracy. She is an active member of international radiological societies, contributing to advancements in the global radiology community.

Professional profile

google scholar

Evaluation of Mansoureh Baradaran, M.D. for the Research for Best Researcher Award

Mansoureh Baradaran, M.D., presents a remarkable profile in radiology research, with a strong international research background. She has participated in numerous collaborative research projects across prestigious institutions such as UCSD, UCLA, and UAB. Her focus on using artificial intelligence in radiology for predictive analysis, as well as her involvement in high-impact studies on topics like Alzheimer’s disease, COVID-19, and cancer, highlights her expertise in radiomics and systematic reviews. Furthermore, Dr. Baradaran has published extensively, with notable research papers in reputable journals, reflecting her capacity for high-quality scholarly output. Her presentations at international conferences like the Society of Interventional Radiology (SIR) 2023 also emphasize her active engagement with the global research community.

Education :

Dr. Mansoureh Baradaran completed her radiology residency at Mashhad University of Medical Sciences, Razavi Khorasan, Iran, between 2016 and 2020. She graduated with a GPA of 17.80/20 and conducted her thesis on the pathologic results of stereotactic core needle biopsy in patients suspicious for malignancy through microcalcifications in mammography. Prior to this, she earned her Doctor of Medicine (M.D.) degree from Birjand University of Medical Sciences, South Khorasan, Iran, in 2016, with a GPA of 18.50/20. Her medical thesis investigated serum lipid levels in patients with thalassemia major compared to the control group. Dr. Baradaran’s education has been rooted in rigorous clinical and research training, allowing her to develop extensive knowledge in radiology, diagnostic imaging, and related research fields. Her educational background reflects a strong commitment to both clinical excellence and research contributions in medical science.

Experience :

Dr. Mansoureh Baradaran currently practices as a radiologist at Dr. Mohajerzadeh Private Radiology Clinic in Bojnurd, Iran, and the Avan Advanced Private Medical Center in Mashhad, Iran. She specializes in performing and interpreting imaging modalities, including ultrasounds, MRI, CT scans, and mammography. Between 2020 and 2024, she worked at North Khorasan University of Medical Science’s hospitals, where she gained extensive experience in diagnostic imaging and reporting across various radiological fields. Dr. Baradaran has also been actively involved in international research collaborations, contributing to studies on artificial intelligence, radiomics, and neurological imaging. These collaborations include working with top institutions like UCLA, UCSD, and UAB on projects such as AI applications in hepatocellular carcinoma recurrence and diagnostic performance of MRI radiomics for Alzheimer’s disease. Her hands-on clinical work is complemented by her commitment to advancing radiological research and diagnostics.

Awards and Honors :

Dr. Mansoureh Baradaran has earned several prestigious accolades throughout her medical and academic career. She secured a double-digit rank in Iran’s highly competitive entrance exam for medical specialties in May 2016, a testament to her academic prowess. Additionally, she achieved national recognition with a high rank in Iran’s basic medical science exam in September 2011. Her exceptional academic performance during her radiology residency, with a GPA of 17.80/20, further highlights her commitment to excellence in her field. Dr. Baradaran’s achievements are not limited to exams; she has co-authored numerous research papers and book chapters, contributing significantly to medical science. Her work in artificial intelligence applications in radiology and diagnostic imaging has been recognized at international conferences such as the Society of Interventional Radiology (SIR) 2023. These awards and honors reflect her dedication to both clinical practice and innovative medical research.

Research Focus :

Dr. Mansoureh Baradaran’s research is focused on diagnostic radiology, radiomics, and the integration of artificial intelligence (AI) in medical imaging. She has contributed to numerous systematic reviews and meta-analyses in areas such as Alzheimer’s disease, lung cancer, and neurological complications related to COVID-19. A significant portion of her research involves the use of radiomics for predictive modeling in diseases like non-small cell lung cancer and hepatocellular carcinoma. Her work aims to enhance diagnostic accuracy through the application of advanced imaging techniques and AI-driven technologies. Dr. Baradaran is particularly interested in how AI can improve the early detection of disease recurrence and optimize treatment outcomes. Additionally, her research on olfactory dysfunction related to COVID-19 has provided valuable insights into the long-term effects of the virus on neuroimaging. Her contributions to radiology extend beyond clinical applications, delving into the future of AI in healthcare diagnostics.

Publications Top Notes:

  1. Diagnostic performance of MRI radiomics for classification of Alzheimer’s disease, mild cognitive impairment, and normal subjects 🧠📊
  2. Prognostic value of CT scan-based radiomics in intracerebral hemorrhage patients 🩸📈
  3. Brain MRI findings in neurologically symptomatic COVID-19 patients 🦠🧠
  4. Legg-Calve-Perthes Disease: A comprehensive review of diagnosis, management, and current treatment options 🦴👩‍⚕️
  5. Diagnostic performance of radiomics in prediction of Ki-67 index status in non-small cell lung cancer 🫁📉
  6. Olfactory dysfunction in the COVID-19 era: An umbrella review focused on neuroimaging 👃🦠
  7. Pathologic results of stereotactic core needle biopsy in patients suspicious to microcalcification on mammography 🔬🩺
  8. Cystic teratoma of the oral cavity 👶👄
  9. Spontaneous rupture of accessory spleen 16 years after splenectomy 🩸🧬
  10. Spontaneous rupture of splenic artery aneurysm in a pregnant woman 🩸🤰

 

Arnulf Stenzl | Health Professions | Academic Excellence Award

Posted on by sciencefather

Prof Dr Arnulf Stenzl | Health Professions | Academic Excellence Award

Prof Dr Arnulf Stenzl, Universität Tübingen, Tübingen Deutschland ,Germany

Prof. Dr. Arnulf Stenzl is an Austrian-born urologist and global leader in urological oncology. He received his medical degree from Karl-Franzens University in Graz, Austria, in 1980 and subsequently trained in surgery and urology across Austria, Switzerland, and the United States. Since 2002, he has headed the Department of Urology at Eberhard-Karls University in Tübingen, Germany, where he oversees critical research on urological cancers. Prof. Stenzl’s contributions extend internationally, with membership in numerous editorial boards and global collaborations. He has played a pivotal role in shaping European urological policies as Secretary General of the European Association of Urology. His work has led to several groundbreaking patents in the field, furthering innovations in patient care.

Professional Profile

Education 

Prof. Dr. Arnulf Stenzl embarked on his academic journey in 1973 when he enrolled at Karl-Franzens University in Graz, Austria, where he earned his Doctor medicinae universalis (M.D.) in February 1980. His initial training spanned internal medicine, nephrology, and pathology at Landeskrankenhaus Klagenfurt and Karl-Franzens University. From 1984 to 1987, he undertook specialized training in urology, first at Karl-Franzens University, then further expanding his knowledge as a fellow in general urology and urologic oncology at the University of California, Los Angeles (UCLA). His education, which encompassed diverse fields such as trauma, vascular, and plastic surgery, provided him with a holistic understanding of medicine and surgery. His dedication to learning has been reflected in his ongoing research and innovative contributions to urology.

Experience 

Prof. Dr. Arnulf Stenzl has had a distinguished career spanning over three decades. After serving as an assistant professor at the University of Bern in Switzerland, he moved to the University of Innsbruck, Austria, where he eventually became vice-chairman of the Department of Urology. Since 2002, he has led the Department of Urology at Eberhard-Karls University Tübingen, Germany, overseeing the clinical, academic, and research arms of the institution. Prof. Stenzl has driven numerous groundbreaking research projects, collaborating with both academic and industrial partners. As Secretary General of the European Association of Urology, he has led European urological research and development initiatives. His expertise extends to cancer research, with numerous contributions to advancing treatment modalities for bladder and prostate cancer.

Awards and Honors 

Prof. Dr. Arnulf Stenzl’s career is marked by numerous prestigious awards and honors. He is an honorary member of several international urological societies, including the Bristol Urological Institute and the Canadian Urological Association. His service as President of the German Urological Association (2020-2021) highlights his leadership within the field. Additionally, his involvement as Chairman of the Scientific Congress Office for the European Association of Urology and his role on the Board of Directors of the European CanCer Organisation demonstrate his commitment to global urological advancement. Prof. Stenzl’s contributions to scientific literature have earned him multiple editorial board memberships. His innovative spirit is further evidenced by several patents, including implantable devices to treat urinary incontinence and risk prediction models for renal cell carcinoma.

Research Focus 

Prof. Dr. Arnulf Stenzl’s research is at the forefront of urological oncology, focusing on advanced treatment modalities for bladder and prostate cancers. His work delves into personalized cancer therapies, optimizing clinical outcomes through precision medicine approaches. A significant aspect of his research revolves around biomarker discovery and risk stratification, which aim to enhance early diagnosis and targeted treatment. He has contributed to pioneering studies in immunotherapy, including innovative techniques for bladder cancer surgery and the integration of novel hormonal therapies in prostate cancer treatment. Prof. Stenzl is also involved in collaborative research projects with industry, furthering the development of next-generation urological treatments. His innovative contributions have resulted in several patents, solidifying his standing as a leader in urological research and technology.

Publications top notes

  • Treatment Intensification With Novel Hormonal Therapy in Prostate Cancer 📚🧪
  • Sacituzumab Govitecan Efficacy in Urothelial Cancer 🧬🔬
  • Co-occurring BRCA2/SPOP Mutations and PARP Inhibitor Sensitivity 🧬⚕️
  • Epacadostat Plus Pembrolizumab for Urothelial Carcinoma 💉🧪
  • Impact of Teratoma on Survival in Germ Cell Cancer 🧫🩺
  • Sacituzumab Govitecan & Pembrolizumab in Urothelial Cancer 💊🧪
  • TROPHY-U-01 Study on Sacituzumab Govitecan in Metastatic Urothelial Cancer 🧬🔬
  • Efficacy of Darolutamide in Black Patients With Prostate Cancer ⚕️🩺
  • Alpha Emitter for Metastatic Castration-Resistant Prostate Cancer 🧬💉